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The article summarizes the proceedings of a symposium on recent advances in research on the patho-
genesis of alcoholic liver disease at the 2001 RSA meeting in Montreal, Canada. The chairs were Amin A.
Nanji and Samuel W. French. The presentations were (1) Role of inflammatory mediators in alcoholic liver
injury by Amin A. Nanji, (2) Role of endotoxin, lipopolysaccharide binding protein, CD14 and Toll
receptors in alcoholic liver injury by Grace Su, (3) Fatty acid ethyl esters: toxicity, metabolism and markers
of ethanol intake by Michael Laposata, and (4) Cyclic changes in gene expression when rats are fed alcohol
at a constant rate by Samuel W. French.




A number of factors are important in the pathogenesis of
alcoholic liver injury. These factors include endotoxin, cytokines
and other proinflammatory mediators, oxidative stress and im-
munologic mechanisms. The mechanisms involved in alcohol-
induced liver injury are not completely understood and are the
subject of investigation in a number of laboratories. Studies
reported here summarize some of areas of research that may
help explain the consequences of alcohol intake.
ROLE OF INFLAMMATORY MEDIATORS IN ALCOHOLIC
LIVER INJURY
Amin A. Nanji
Recently, there has been an explosion of knowledge
about inflammatory mediators that are involved in the
pathogenesis of alcoholic liver disease. However, it is not
clear as yet how this work will influence our understanding
of the pathogenesis of alcoholic liver disease or its treat-
ment. For example, evidence has accumulated that Kupffer
cells are an important source of inflammatory mediators
and inhibition of Kupffer cell function leads to ameliora-
tion of alcoholic liver injury. Also, TNF- released by
Kupffer cells is important in liver regeneration.
One major mediator of the effects of endotoxin and
oxidative stress is nuclear factor kappa B (NF-B). NF-B
is a ubiquitous transcription factor that is implicated in the
activation of several genes involved in inflammation.
NF-B is sequestered in the cytoplasm through its interac-
tion with IB proteins. Activation of NF-B occurs in rats
fed ethanol intragastrically in association with endotox-
emia, increased oxidative stress and liver injury (Nanji et
al., 1999). Monocytes from patients with alcoholic hepatitis
also display greater NF-B activity than monocytes from
control subjects (Hill et al., 2000). Although NF-B is a
potential target for treatment of inflammatory liver injury,
it should be noted that inhibition of NF-B can initiate
fulminant hepatic failure (Beg and Baltimore, 1998).
Among the genes activated by NF-B is cyclooxygenase-2
(Cox-2) (Nanji et al., 1999). An important pivotal observation
linking Cox-2 to hepatocellular injury is the study by Dinchuk
et al. (1995) in Cox-2 deficient mice. Cox-2 deficient mice sensi-
tized to TNF--induced hepatotoxicity with D-galactosamine
are protected against liver injury. In ethanol-fed rats, in-
creased expression of Cox-2, mainly in Kupffer cells, is asso-
ciated with endotoxemia, oxidative stress and pathologic liver
injury (Nanji et al., 1997). These studies suggest a role for both
Cox-2 and TNF- in promoting alcoholic liver injury. The
importance of TNF- and Cox-2 in promoting liver injury is
further supported by studies in female rats fed fish oil and
dextrose (Nanji et al., 2001). Male and female rats fed fish oil
and dextrose show increased expression of TNF-, but only
female rats have increased expression of Cox-2 and show
evidence of liver injury.
ROLE OF ENDOTOXIN, LBP, CD14, AND TOLL
RECEPTORS IN ALCOHOLIC LIVER INJURY
Grace Su
Multiple lines of evidence support the hypothesis that en-
dotoxin or lipopolysaccharide (LPS) is an important cofactor
in the pathogenesis of liver injury. This has been best delin-
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eated in alcohol-induced liver injury. In the Tsukomoto and
French model of alcoholic liver disease, there is a strong
correlation between the degree of liver injury and endotox-
emia (Nanji et al., 1993). The pathway by which LPS contrib-
utes to liver injury is postulated to be via Kupffer cell activa-
tion. Located in the sinusoidal space, Kupffer cells are in
contact with portal blood which drains the intestinal tract.
They are thus exposed to bacteria and bacterial products, such
as LPS, which traverse the intestinal barrier. Kupffer cells are
important in clearing LPS but its interactions with LPS are not
limited to clearance. Kupffer cells, when exposed to LPS, can
be activated to produce a spectrum of cytokines and reactive
oxygen intermediates. These inflammatory mediators, such as
TNF-, can contribute to further liver injury. In human alco-
holic hepatitis, elevations of TNF- are associated with a
worse prognosis (Felver et al., 1990) and treatments such as
corticosteroids and pentoxifylline which can diminish immune
activation have been shown to have some benefit. In rodent
models of alcoholic hepatitis, an important role for TNF- in
mediating liver injury has been provided by in vivo studies
using anti-TNF- antibodies and TNF receptor 1 knockout
mice (Iimuro et al., 1997; Yin et al., 1999). A role for Kupffer
cell activation in this pathway is supported by studies showing
significantly less liver injury in the presence of antibiotics,
lactobacillus, or gadolinium chloride (Adachi et al., 1995);
(Adachi et al.,1994); (Nanji et al., 1994).
Despite its importance, the mechanism by which LPS
activates Kupffer cells is not entirely clear. In peripheral
blood monocytes, LPS activation is mediated through LPS
binding protein (LBP) and CD14. In serum, LPS binds to
LBP, a 60kDa glycoprotein produced predominantly by the
liver and secreted in serum (Schumann et al., 1990; Wright
et al., 1990). LBP catalyzes the transfer of LPS to cell
surface receptors such as membrane CD14 (Hailman et al.,
1994) which shuttles it to the downstream receptor, toll-like
receptor 4 (TLR4). In the presence of LBP, markedly less
LPS is needed to activate peripheral blood monocytes. The
LBP and CD14/TLR4 pathway is critical for interactions at
the low concentrations of LPS found under physiologic
conditions. We have previously shown that LBP and CD14
are increased in alcohol-induced liver injury and appear to
correlate with the degree of liver injury (Su et al., 1998).
Because Kupffer cells have relatively low baseline expres-
sion of CD14 (Takai et al., 1997; Ziegler-Heitbrock and
Ulevitch 1993), some have suggested that Kupffer cells may
behave differently from peripheral blood monocytes in re-
gards to LPS. Furthermore, Kupffer cells and other mac-
rophages can interact with LPS in a serum-independent
fashion (Lichtman et al., 1998; Bellezzo et al., 1996). This
has led some to suggest that Kupffer cell activation by LPS
is mediated not through the LBP/CD14/TLR4 pathway but
rather through some less well characterized pathways (Li-
chtman et al., 1998; Bellezzo et al., 1996).
Su et al., present data showing the role of LBP, CD14 and
TLR4 in Kupffer cell activation (Su et al., 2000; Su et al.,
2002). Using primary cultures of isolated Kupffer cells, they
demonstrated that isolated Kupffer cells express both mCD14
and TLR4 receptors. Kupffer cells were then incubated with
varying concentrations of LPS for 6 hr in the presence and
absence of recombinant LBP. The supernatant was then mea-
sured for TNF- as a marker of Kupffer cell activation. Iso-
lated Kupffer cells produce little baseline TNF-. In the pres-
ence of increasing concentrations of LPS, more TNF- was
produced. TNF- was produced in response to LPS irrespec-
tive of the presence of LBP; however, at low concentrations of
LPS (1 and 10 ng/ml), significantly more TNF- was produced
in the presence of LBP. A functional role for CD14 and TLR4
in mediating Kupffer cell activation was demonstrated using
CD14 deficient and TLR4 mutant animals. Kupffer cells iso-
lated from CD14-deficient or TLR4 mutant (C3H/HeJ) ani-
mals produced little TNF- in response to LPS both in the
presence and absence of LBP, suggesting that both LBP-
dependent and independent pathways of LPS activation occur
via this critical receptor pathway. The role of CD14 in Kupffer
cell activation was further supported using human Kupffer
cells and well characterized anti-CD14 monoclonal antibod-
ies. Isolated human Kupffer cells respond to LPS in a dose-
dependent manner which was blocked in the presence of the
inhibitory anti-CD14 antibody, MY4, but not in the presence
of LeuM3, an antibody which recognizes CD14, but does not
block cellular activation by LPS.
The bioactivity of LBP is determined by its concentra-
tion. At low concentrations, LBP augments Kupffer cell
activation but at high concentrations, this biological activity
is not present. In the presence of higher concentrations of
LBP, which might be seen in the acute phase response, the
ability of LBP to augment phagocytosis of Gram-negative
bacteria remains intact. To examine the role of LBP in liver
injury, LBP knockout and wildtype animals were given an
intraperitoneal injection of carbon tetrachloride and liver
histology examined. At day 1, both LBP knockout and
wildtype animals had significant liver necrosis due to the
CCl4. However, by day 5, LBP wildtype animals had histo-
logic improvement while LBP knockout animals continued
to have significant necrosis. This suggests a protective role
of LBP in the pathogenesis of CCl4-induced liver injury.
The mechanism for this protection is a subject of ongoing
research. However, this data supports the hypothesis that
endotoxin and mediators of endotoxin-induced cellular ac-
tivation such as LBP, CD14 and TLR4 play a role in the
pathogenesis of liver injury.
FATTY ACID ETHYL ESTERS: TOXICITY, METABOLISM,
AND MARKERS OF ETHANOL INTAKE
Michael Laposata
Fatty acid ethyl esters (FAEE) are nonoxidative metab-
olites of ethanol. The synthesis of fatty acid ethyl esters in
vivo is poorly understood as many diverse enzymes have
been identified as contributory to the synthesis of fatty acid
ethyl esters from ethanol. A 1986 report demonstrated that
the organs most frequently damaged by ethanol abuse,
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notably pancreas and liver, were found to have the highest
levels of fatty acid ethyl esters and the enzymes responsible for
their synthesis in patients who died while intoxicated with
ethanol (Laposata and Lange, 1986). A technical develop-
ment which has spurred the study of FAEE in vitro and in vivo
was the solubilization (in aqueous medium) of FAEE in the
core of isolated human low density lipoprotein (LDL) parti-
cles, previously delipidated to remove the core trigylceride
and cholesterol ester (Bird et al., 1995). Another was the use
of gas chromatography-mass spectrometry (GC-MS) for the
quantitation of FAEE for conclusive identification (Laposata
et al., 1995; Zybko et al., 2001).
Toxicity of FAEE. Initial studies on the toxicity of FAEE
involved the use of HepG2 cells incubated with either native
low density lipoprotein or low density lipoprotein reconsti-
tuted with FAEE. The addition to the medium of particles
containing FAEE resulted in decreased [3H]thymidine incor-
poration into the cells, as well as decreased 35S-methionine
incorporation into cellular protein (Szczepiorkowski et al.,
1995). The concentrations of FAEE used in these studies
which produced these toxic effects in liver-derived HepG2
cells was 100 - 200 M and above. Plasma concentrations of
FAEE up to 41 M are found in chronic alcoholics; for this
reason, an in vivo study with rats was performed using 11 M
FAEE, a concentration easily attainable by ethanol consump-
tion, and damage to both liver and pancreas was assessed
(Werner et al., 1997). In this in vivo study, LDL reconstituted
with either cholesterol ester or with FAEE was infused into
rats as an intra-arterial bolus with an additional 3 hr of infu-
sion. Rats receiving FAEE-laden lipoproteins showed pancre-
atic damage and the rats receiving non-FAEE containing
lipoproteins showed no injury. There was no evidence of liver
damage in either group, suggesting that the pancreas is more
susceptible to injury by FAEE from a single exposure than is
the liver. Studies in which multiple inhibitors of oxidative
ethanol metabolism have been added to cultured cells and
administered in vivo to animals exposed to ethanol have been
performed, and in both cases there was an increase in FAEE
(Werner et al., 2001). This demonstrated that there is a link-
age between the oxidative and nonoxidative pathways of eth-
anol metabolism, whereby a blockage of the oxidative pathway
results in increased flux through the nonoxidative pathway.
There was also a corresponding increase pancreatic damage in
the in vivo study further supporting the conclusion that FAEE
can induce cell injury.
FAEE Synthesis. The HepG2 cell model has been utilized
to study the synthesis of FAEE (Kabakibi et al., 1998). These
cells produce FAEE when incubated with ethanol at physio-
logic concentrations. The production of FAEE can be as-
sessed by the measurement of FAEE in the cells, and secre-
tion of FAEE can be assessed by the quantitation of FAEE in
the medium. Our data have led us to propose a mechanism for
the synthesis and transport of FAEE within HepG2 cells
which involves the synthesis of the FAEE molecule in the
microsomes of the cell, subsequent binding to fatty acid bind-
ing protein (FABP), and movement of the FAEE to the
plasma membrane. At this point, the FAEE are removed
from the cell by lipoproteins and albumin for transport in the
circulation. Numerous studies have been performed to deter-
mine the source of the fatty acid within the cell for FAEE
synthesis. Thus far, addition of all fatty acids except for palmi-
tate to the extracellular medium results in an increase in the
production of FAEE in HepG2 cells, with the added fatty acid
as prominent among those found in FAEE (Dan and Lapo-
sata, 1997). Furthermore, the fatty acids which are most newly
incorporated into cells are preferred for FAEE synthesis over
those fatty acids which have been in the cells for longer
periods of time (Dan and Laposata, 1998).White blood cells,
particularly the natural killer (NK) cells, contain measurable
amounts of FAEE synthetic enzymes (Gorski et al., 1996).
Using white blood cell FAEE synthetic activity (which one
does not need a liver or pancreatic biopsy to obtain), it has
been demonstrated that the enzymes for FAEE synthesis are
induced by up to 6 days of daily intake of ethanol, but with
continued ethanol intake, the enzyme activity decreases to
below baseline levels. Chronic alcoholics have lower FAEE
synthase activity in their white blood cells than nonalcoholics.
In a separate set of experiments, purified FAEE synthase was
shown to have a synthetic capacity for cocaethylene, a metab-
olite of cocaine (Heith et al., 1995). Patients who have abnor-
malities in liver or pancreatic function, reflective of injury to
these organs, also release FAEE synthetic activity into the
circulating blood (Al-Eryani et al., 1996). Thus, it is suspected
that with liver damage, FAEE synthesis does not only occur in
solid organs and intact cells, but also in the plasma secondary
to the release of the cytoplasmic FAEE synthetic activity from
damaged hepatocytes, and possibly pancreatic acinar cells,
into the blood.
FAEE Secretion. Addition of lipoproteins or albumin to the
culture medium of HepG2 cells stimulates FAEE secretion
when the cells are exposed to ethanol (Hasaba and Laposata,
2001). Albumin does not result in an increase in FAEE syn-
thesis in the cells, but does induce a redistribution of FAEE
from the cells to the extracellular medium. Both HDL and
LDL, however, induce a redistribution to the extracellular
medium and also stimulate the cells to produce more FAEE.
The FAEE species which are secreted into the blood are
different from the FAEE which are present within the organs
exposed to ethanol, suggesting some selectivity among FAEE
molecules for release from the cell (Dan and Laposata, 1998).
Also, the fatty acid composition of the FAEE in the blood is
different from the fatty acid composition of the FAEE in the
liver, which is presumably the major site of origin of plasma
FAEE. Similarly, the fatty acid composition of FAEE differs
between pancreas and pancreatic secretions and the fatty acid
composition of FAEE in liver and bile is also different (La-
posata et al., 2000). The selective secretion of specific FAEE
species may be important if certain FAEE species are more
toxic than others. Such a difference in toxicity remains to be
demonstrated.
FAEE Transport in the Blood. FAEE are bound to albu-
min of the plasma in intoxicated individuals (Doyle et al.,
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1994), and free fatty acids displace ethyl 14C-ethyl oleate from
albumin. Thus, there is rapid transfer of FAEE between
phospholipid bilayers and LDL, thereby demonstrating that
the exchange from a cell membrane to a circulating lipopro-
tein particle is efficient and rapid (Bird et al., 1996). FAEE
localizes to the core of the lipoproteins, and that as the FAEE
concentration increases in the blood, a higher percentage of
the FAEE is found in lipoproteins relative to albumin (Bird et
al., 1997).
FAEE Degradation. FAEE within the core of an LDL
particle injected into rats results in the degradation of the
FAEE with a half-life of only 58 sec (Saghir et al., 1997).
The degradation is caused by the cellular elements of the
blood, as cell-free plasma does not produce a similar effect
(Saghir et al., 2000). Also, the metabolic fate of fatty acid
released from the FAEE, when degradation separates the
ethanol and fatty acid moieties, depends upon the organ or
tissue in which the FAEE is degraded and the metabolic
pathways for that specific fatty acid (Saghir et al., 1997).
FAEE as Markers of Ethanol Intake. FAEE is detected in
blood, long after ethanol has become undetectable in the
circulation and is therefore a marker of ethanol intake (Doyle
et al., 1996; Salem et al., 2001a). The type of alcoholic bever-
age ingested has no impact on the plasma FAEE levels
(Soderberg et al., 1999). Even though women have higher
blood ethanol levels after ethanol intake relative to men with
an equivalent weight-based intake of ethanol, men develop
FAEE levels that are 2-fold higher than women. Concentra-
tions of ethyl oleate in chronic alcoholics and episodic heavy
drinkers are significantly different at or near peak blood eth-
anol concentrations (Soderberg et al., 2001). Thus, the pres-
ence of this particular fatty acid (oleate) in the FAEE can
separate chronic alcoholics and from binge drinkers. After 24
hr of alcohol abstinence, ethyl oleate was an even better
differentiating marker between chronic alcoholics and binge
drinkers.In studies carried out in rats, it has been shown that
intake of ethanol prior to death results in the presence of
FAEE in the liver and in adipose tissue, and that the presence
FAEE in these sites can serve as a marker of premortem
ethanol intake (Salem et al., 2001b). In a human study with 31
autopsied cases from the hospital and medical examiners
office, with postmortem intervals ranging from 5 to 29 hr,
blood ethanol concentration was determined but not made
known to the laboratory measuring FAEE (Refaai et al.,
2001). Correct identification of individuals with a detectable
blood ethanol level at autopsy, chronic alcoholics with no
detectable blood ethanol at autopsy and social drinkers (with
a negative blood ethanol at autopsy) was possible because of
the presence of FAEE in the liver. In addition, the concen-
tration of ethyl arachidonate (a specific species of FAEE) was
useful because it was found only in individuals with a detect-
able blood ethanol at the time of autopsy.
Summary. FAEE are ethanol metabolites that have been
shown to be toxic both in vitro and in vivo. Their synthesis,
secretion, and degradation has been investigated in many
studies, and substantial information has been accumulated
over the past decade on these metabolic pathways. The use
of FAEE both in blood and in solid organs as markers of
ethanol intake continues to advance.
CYCLIC CHANGE IN GENE EXPRESSION WHEN RATS
ARE FED ALCOHOLIC AT A CONSTANT RATE
Samuel W. French
The blood alcohol levels (BAL) of rats fed ethanol at a
constant rate intragastrically through a permanent cannula,
cycle between 100 mg% to 500 mg% (Tsukamoto et al.,
1985a). When the BAL falls the rate of ethanol elimination
increases and vice versa. The daily urine alcohol levels (UAL)
were measured to follow the peaks and troughs because UAL
is proportionate to BAL when ethanol is fed at a constant rate
(i.e., 13 g/kg/day). The rationale for studying this intriguing
phenomenon is that the amplitude of the oscillation correlates
with the worsening of the liver pathology (Tsukamoto et al.,
1985b). The study of this phenomenon has provided two
important observations which are reported here. 1) The cy-
cling of the elimination rate of blood alcohol requires oscilla-
tion of the metabolic rate which is regulated by the change in
thyroid hormone levels. The hormone levels are driven by
changes in the body temperature induced by the fluctuations
in BAL (Li et al., 2001a). The cycle is prevented by giving
propylthiouracil, cutting the pituitary stalk or feeding T4. T4
treatment prevents the alcohol-induced liver pathology but
causes submassive necrosis and fibrosis in the ethanol-fed rats
(Li et al., 2001b). 2) Gene expression fluctuates during the
cycle in a way that is similar to the ischemia/reperfusion model
of liver injury.
With regards to the first observation, the severity of the
pathology was greater at the peaks of the cycle. The serum
LPS levels were greater at the peaks but TNF levels were
similarly elevated at both the peaks and troughs of the
cycle. ALT levels were greater at the troughs indicating that
necrosis was greater at the troughs. The pattern of liver
injury at the peaks and troughs was consistent with hypoxic
injury at the peaks and reperfusion injury at the troughs.
The evidence for hypoxic injury was that the liver ATP
levels were markedly reduced at the peaks but not at the
troughs (French , 2000). NADH/NAD levels were mark-
edly increased at the peaks but not at the troughs. This was
because 02 is required to regenerate NAD from NADH in
the electron transport chain in the mitochondria. The hy-
poxyprobe immunofluorescent method of measuring hyp-
oxia in vivo in the liver (Arteel et al., 1996) showed that the
livers were hypoxic at the peaks but not at the troughs.
The genes expression patterns vary during the UAL
cycle, depending on the particular gene. The expression is
up-regulated, down-regulated or unchanged at the UAL
peaks and troughs compared with controls (Shahed et al.,
2001, French , 2000). When genes regulated by the HIF-1
transcription factor were measured by RT PCR, vascular
endothelial growth factor (VEGF) was up-regulated at
both the peaks and troughs compared to controls. Western
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blot analysis done by using an antibody to VEGF showed
an increase in protein only at the peaks when hypoxia of the
liver was manifested. Another gene, erythropoietin, which
is up-regulated by hypoxia, was up-regulated only at the
peaks. Hemoxygenase, a third hypoxia regulated gene was
not changed.
Oxidative stress related genes such as CYP2El, iNOS
and COX-2 were variously expressed at the peaks and
troughs of the UAL cycle. CYP2E1 was up-regulated at the
peaks and troughs as assessed by RT-PCR. CYP2E1 was
upregulated only at the peaks when Northern blots and
microarray gene analysis were done. Inducible NO synthase
(iNOS), a mitochondrial protein was down-regulated at the
troughs. Immunofluorescence of liver sections at the
troughs showed loss of mitochondrial iNOS in the centri-
lobular hepatocytes. Thus the protective role of NO as an
antioxidant may have been reduced at the troughs.
The gene expression of cytokines (TNF) and chemo-
kines (MCP-1) were also differentially altered at the peaks
and troughs. Although TNF was not changed, MCP-1 was
upregulated at the peaks compared to the troughs. This
could be one factor which mediated the inflammation seen
in livers at the peaks. MCP-1 production was increased by
blood monocytes of patients during alcoholic hepatitis (De-
valaraja et al., 1999).
The expression of apoptotic-associated genes BAX, Bc12,
FAS and FASL were measured but only BAX was up-
regulated at the troughs compared with the peaks and con-
trols. This was associated with an increase in apoptosis seen in
livers at the troughs which were stained using TUNEL.
The gene expression of growth factors were also differ-
entially changed at the peaks and troughs. Connective tis-
sue growth factor (CTGF) was up-regulated at both the
peaks and troughs. CTGF is involved in hepatocellular
carcinoma formation (Hirasaki et al., 2001). The Western
blot using c-fos antibody showed an increase at the troughs
compared to controls and peaks. Microarray gene analysis
showed that IGF-1 was increased at the troughs compared
with the peaks. JUN was increased at troughs compared to
the peaks. Thus gene expression upregulation which sup-
ports liver cell regeneration was found at the troughs.
Genes up-regulated at the peaks compared to the
troughs found on microarray gene analysis were as follows
(French , 2000); MAP kinase 3, DNA-damage-inducible
protein 45, D-amino acid oxidase, catechol-O-methyl trans-
ferase, tyrosine, phosphatase-like protein, fatty acid syn-
thetase and fatty acid binding protein in liver. Cytochrome
P-450 isozymes and reductases and ADH isozymes were
up-regulated at the peaks as follows: P-450 2A1, CYP450
14 DM, CYP11A1, ADH-1, NADH-cyto b5 reductase and
NADPH-CYP450 reductase.
In summary, changes in gene expression are different at
high and low UAL during the cycle. Many are increased
during the peaks when hypoxia and a shift in the NADH/
NAD redox state exists. Other genes involved in growth,
apoptosis and mitochondrial antioxidant activity are in-
creased at the troughs of the UAL cycle, when reperfusion-
like injury occurs. It is important to control for the influ-
ence of BAL on gene expression when studying
experimental alcoholic liver disease (Li, 2002).
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